Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)

por Cohan, Stanley L., Hendin, Barry A., Reder, Anthony T., Smoot, Kyle, Avila, Robin, Mendoza, Jason P., Weinstock-Guttman, Bianca
Publicado 2021

Peripheral nervous system manifestations in a Sandhoff disease mouse model: nerve conduction, myelin structure, lipid analysis

por McNally, Melanie A, Baek, Rena C, Avila, Robin L, Seyfried, Thomas N, Strichartz, Gary R, Kirschner, Daniel A
Publicado 2007

Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple S...

por Repovic, Pavle, Robertson, Derrick, Kresa-Reahl, Kiren, Cohan, Stanley L., Su, Ray, Avila, Robin, Koulinska, Irene, Mendoza, Jason P.
Publicado 2020

Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing–Remitting Multiple Sclerosis: STRIVE Data Analysis

por Perumal, Jai, Balabanov, Roumen, Balcer, Laura, Galetta, Steven, Sun, Zhaonan, Li, Hanyue, Rutledge, Danette, Avila, Robin L., Fox, Robert J.
Publicado 2023

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy

por Jaber, Aliya, Patel, Meera, Sylvester, Andrew, Yarussi, Mary, Kalina, J. Tamar, Mendoza, Jason P., Avila, Robin L., Tremblay, Matthew A.
Publicado 2023

Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Nata...

por Perumal, Jai, Balabanov, Roumen, Su, Ray, Chang, Roger, Balcer, Laura J., Galetta, Steven L., Avila, Robin L., Rutledge, Danette, Fox, Robert J.
Publicado 2023

Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Result...

por Perumal, Jai, Balabanov, Roumen, Su, Ray, Chang, Roger, Balcer, Laura J., Galetta, Steven L., Avila, Robin L., Rutledge, Danette, Fox, Robert J.
Publicado 2022

Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis

por O'Leary, Shirley, Brugger, Helen T., Wallentine, Dale, Sershon, Lisa, Goff, Erica, Saldana-King, Toni, Beavin, Jill, Avila, Robin L., Rutledge, Danette, Moore, Marie
Publicado 2023

Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study

por Perumal, Jai, Balabanov, Roumen, Su, Ray, Chang, Roger, Balcer, Laura, Galetta, Steven, Campagnolo, Denise I., Avila, Robin, Lee, Lily, Rutledge, Danette, Fox, Robert J.
Publicado 2021

Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study

por Perumal, Jai, Balabanov, Roumen, Su, Ray, Chang, Roger, Balcer, Laura, Galetta, Steven, Campagnolo, Denise I., Avila, Robin, Lee, Lily, Rutledge, Danette, Fox, Robert J.
Publicado 2021